Amneal Pharmaceuticals (AMRX)
(Delayed Data from NSDQ)
$7.45 USD
+0.21 (2.90%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $7.45 0.00 (0.00%) 5:36 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.45 USD
+0.21 (2.90%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $7.45 0.00 (0.00%) 5:36 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Zacks News
Amneal (AMRX) Shares Down on CRL for Parkinson's Disease Drug
by Zacks Equity Research
Amneal (AMRX) suffers a setback as the FDA issues a complete response letter (CRL) to its new drug application (NDA) for IPX203 for treating Parkinson's disease.
Earnings Preview: Theravance Biopharma (TBPH) Q1 Earnings Expected to Decline
by Zacks Equity Research
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 9.52% and 4.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review
by Zacks Equity Research
Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 3.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Q3 Earnings Miss Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of -52.27% and 1.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Amneal Pharmaceuticals (AMRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amneal Pharmaceuticals (AMRX) stock based on the movements in the options market lately.
Amneal Pharmaceuticals (AMRX) Lags Q2 Earnings Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of -5% and 4.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Q1 Earnings Meet Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 0% and 0.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Lags Q4 Earnings Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of -5.26% and 1.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amneal Pharmaceuticals (AMRX) and Athersys, Inc. (ATHX) have performed compared to their sector so far this year.
Is Amneal Pharmaceuticals (AMRX) a Suitable Pick for Value Investors?
by Zacks Equity Research
Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.
Amneal Pharmaceuticals (AMRX) Tops Q3 Earnings Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 5.00% and -3.27%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Amneal (AMRX)
by Zacks Equity Research
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study
by Zacks Equity Research
Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 38.89% and 1.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMRX vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMRX vs. ZTS: Which Stock Is the Better Value Option?
AMRX or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMRX vs. ZTS: Which Stock Is the Better Value Option?
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 11.11% and -2.81%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 7.69% and 1.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?